Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas

W. K Alfred Yung, Todd J. Janus, Moshe Maor, Lynn G Feun

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Forty-five patients with malignant gliomas were treated after aggressive surgical resection with alternating intravenous carmustine and cisplatin both during and after radiation therapy. Thirty-three patients were considered evaluable for responses, 17 had glioblastoma multiforme (GBM),14 had anaplastic astrocytoma (AA) and 2 had anaplastic oligodendroglioma (AO). The median age of the evaluable patients was 47 years. The median time to tumor progression was 34.5 weeks, and the median survival for the entire group was 76 weeks. Early progression occurred more frequently in patients with glioblastoma than in those with AA or AO. Seventeen patients (55%) were alive at 18 months (6 GBM, 9 AA, 2 AO). Toxicity was mainly hematologic, otic and tolerable. The results suggest that further trial is warranted to assess the efficacy of alternating carmustine and cisplatin in conjunction with radiation therapy postoperatively in patients with malignant gliomas.

Original languageEnglish
Pages (from-to)131-135
Number of pages5
JournalJournal of Neuro-Oncology
Volume12
Issue number2
DOIs
StatePublished - Feb 1 1992
Externally publishedYes

Fingerprint

Carmustine
Adjuvant Chemotherapy
Glioma
Cisplatin
Oligodendroglioma
Astrocytoma
Glioblastoma
Radiotherapy
Ear
Survival
Neoplasms

Keywords

  • carmustine
  • chemotherapy
  • cisplatin
  • malignant gliomas

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. / Yung, W. K Alfred; Janus, Todd J.; Maor, Moshe; Feun, Lynn G.

In: Journal of Neuro-Oncology, Vol. 12, No. 2, 01.02.1992, p. 131-135.

Research output: Contribution to journalArticle

Yung, W. K Alfred ; Janus, Todd J. ; Maor, Moshe ; Feun, Lynn G. / Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. In: Journal of Neuro-Oncology. 1992 ; Vol. 12, No. 2. pp. 131-135.
@article{84a716dfaefd445b80030a03ae533d24,
title = "Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas",
abstract = "Forty-five patients with malignant gliomas were treated after aggressive surgical resection with alternating intravenous carmustine and cisplatin both during and after radiation therapy. Thirty-three patients were considered evaluable for responses, 17 had glioblastoma multiforme (GBM),14 had anaplastic astrocytoma (AA) and 2 had anaplastic oligodendroglioma (AO). The median age of the evaluable patients was 47 years. The median time to tumor progression was 34.5 weeks, and the median survival for the entire group was 76 weeks. Early progression occurred more frequently in patients with glioblastoma than in those with AA or AO. Seventeen patients (55{\%}) were alive at 18 months (6 GBM, 9 AA, 2 AO). Toxicity was mainly hematologic, otic and tolerable. The results suggest that further trial is warranted to assess the efficacy of alternating carmustine and cisplatin in conjunction with radiation therapy postoperatively in patients with malignant gliomas.",
keywords = "carmustine, chemotherapy, cisplatin, malignant gliomas",
author = "Yung, {W. K Alfred} and Janus, {Todd J.} and Moshe Maor and Feun, {Lynn G}",
year = "1992",
month = "2",
day = "1",
doi = "10.1007/BF00172662",
language = "English",
volume = "12",
pages = "131--135",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas

AU - Yung, W. K Alfred

AU - Janus, Todd J.

AU - Maor, Moshe

AU - Feun, Lynn G

PY - 1992/2/1

Y1 - 1992/2/1

N2 - Forty-five patients with malignant gliomas were treated after aggressive surgical resection with alternating intravenous carmustine and cisplatin both during and after radiation therapy. Thirty-three patients were considered evaluable for responses, 17 had glioblastoma multiforme (GBM),14 had anaplastic astrocytoma (AA) and 2 had anaplastic oligodendroglioma (AO). The median age of the evaluable patients was 47 years. The median time to tumor progression was 34.5 weeks, and the median survival for the entire group was 76 weeks. Early progression occurred more frequently in patients with glioblastoma than in those with AA or AO. Seventeen patients (55%) were alive at 18 months (6 GBM, 9 AA, 2 AO). Toxicity was mainly hematologic, otic and tolerable. The results suggest that further trial is warranted to assess the efficacy of alternating carmustine and cisplatin in conjunction with radiation therapy postoperatively in patients with malignant gliomas.

AB - Forty-five patients with malignant gliomas were treated after aggressive surgical resection with alternating intravenous carmustine and cisplatin both during and after radiation therapy. Thirty-three patients were considered evaluable for responses, 17 had glioblastoma multiforme (GBM),14 had anaplastic astrocytoma (AA) and 2 had anaplastic oligodendroglioma (AO). The median age of the evaluable patients was 47 years. The median time to tumor progression was 34.5 weeks, and the median survival for the entire group was 76 weeks. Early progression occurred more frequently in patients with glioblastoma than in those with AA or AO. Seventeen patients (55%) were alive at 18 months (6 GBM, 9 AA, 2 AO). Toxicity was mainly hematologic, otic and tolerable. The results suggest that further trial is warranted to assess the efficacy of alternating carmustine and cisplatin in conjunction with radiation therapy postoperatively in patients with malignant gliomas.

KW - carmustine

KW - chemotherapy

KW - cisplatin

KW - malignant gliomas

UR - http://www.scopus.com/inward/record.url?scp=0026595777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026595777&partnerID=8YFLogxK

U2 - 10.1007/BF00172662

DO - 10.1007/BF00172662

M3 - Article

VL - 12

SP - 131

EP - 135

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -